Page last updated: 2024-12-08

1-(3-astatobenzyl)guanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're asking about **1-(3-azatobenzyl)guanidine**, also sometimes referred to as **1-(3-pyridinylmethyl)guanidine**.

Let's break down why this compound is interesting for research:

**What it is:**

* **Guanidine:** This is a nitrogen-rich functional group commonly found in biologically important molecules like arginine.
* **3-Azatobenzyl:** This part refers to a benzyl group (a benzene ring with a CH2 group attached) where one of the carbon atoms in the ring has been replaced by a nitrogen atom (creating a pyridine ring).

**Why it's important for research:**

* **Potential therapeutic target:** Guanidines can interact with specific targets in the body, making them valuable for drug discovery. 1-(3-azatobenzyl)guanidine has shown potential as a:
* **Anti-inflammatory agent:** Some studies suggest it can reduce inflammation, which is crucial in treating various diseases.
* **Anti-cancer agent:** It may exhibit cytotoxic effects (killing cancer cells) and potentially interfere with cancer cell growth and proliferation.
* **Anti-microbial agent:** It might be effective against certain bacteria or fungi.
* **Versatile building block:** This compound can be used as a starting point to synthesize a variety of other molecules with potential medicinal applications.

**Current research:**

* **Limited clinical data:** While pre-clinical studies have shown promising results, clinical trials in humans are still limited for 1-(3-azatobenzyl)guanidine.
* **Mechanism of action:** Researchers are still working to fully understand how this compound interacts with various biological targets and how it exerts its effects.

**Overall:** 1-(3-azatobenzyl)guanidine is a molecule with potential applications in various fields. Further research is needed to fully evaluate its therapeutic potential and clarify its mechanism of action.

1-(3-astatobenzyl)guanidine: structure given in first source; might prove useful for treating neuroblastoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164244
MeSH IDM0210819

Synonyms (8)

Synonym
211at-mabg
127367-45-7
1-(m-astatobenzyl)guanidine
1-(3-astatobenzyl)guanidine
guanidine, ((3-(astato-(211)at)phenyl)methyl)-
[3-(carbamimidamidomethyl)phenyl](~211~at)astatine
DTXSID60925866
[3-[(diaminomethylideneamino)methyl]phenyl](211at)astatine-211

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The Auger electron-emitting conjugates ([123I]MIBG and [125I]MIBG) and the alpha-emitting conjugate ([211At]MABG) were highly toxic to monolayers and small spheroids, whereas the beta-emitting conjugate [131I]MIBG was relatively ineffective."( Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Cunningham, SH; Mairs, RJ; Vaidyanathan, G; Welsh, PC; Wheldon, TE; Zalutsky, MR, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.18 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]